GlaxoSmithKline Pakistan (KAR:GLAXO) Change In Payables And Accrued Expense : ₨0 Mil (TTM As of Mar. 2025)

View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Change In Payables And Accrued Expense?

GlaxoSmithKline Pakistan's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was ₨0 Mil. It means GlaxoSmithKline Pakistan's Accounts Payable & Accrued Expense stayed the same from Dec. 2024 to Mar. 2025 .

GlaxoSmithKline Pakistan's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was ₨0 Mil. It means GlaxoSmithKline Pakistan's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

GlaxoSmithKline Pakistan Change In Payables And Accrued Expense Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan Change In Payables And Accrued Expense Chart

GlaxoSmithKline Pakistan Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

GlaxoSmithKline Pakistan Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

GlaxoSmithKline Pakistan Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨0 Mil.

GlaxoSmithKline Pakistan Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pakistan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

35, Dockyard Road, West Wharf, Karachi, PAK, 74000

Website

https://www.pk.gsk.com

GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines